Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies
Leon F. Garcia-Martinez, Woodinville, WA (US); Anne Elisabeth Carvalho Jensen, Mill Creek, WA (US); Katie Anderson, Kirkland, WA (US); Benjamin H. Dutzar, Seattle, WA (US); Ethan W. Ojala, Snohomish, WA (US); Brian R. Kovacevich, Snohomish, WA (US); John A. Latham, Seattle, WA (US); and Jeffrey T. L. Smith, Dublin (IE)
Assigned to Vitaeris Inc., Vancouver (CA)
Filed by VITAERIS INC., Vancouver (CA)
Filed on Nov. 11, 2020, as Appl. No. 17/095,136.
Application 16/356,468 is a division of application No. 15/668,989, filed on Aug. 4, 2017, granted, now 10,233,239, issued on Mar. 19, 2019.
Application 15/668,989 is a division of application No. 14/604,366, filed on Jan. 23, 2015, granted, now 9,725,509, issued on Aug. 8, 2017.
Application 13/298,407 is a division of application No. 12/366,567, filed on Feb. 5, 2009, granted, now 8,062,864, issued on Nov. 22, 2011.
Application 17/095,136 is a continuation of application No. 16/356,468, filed on Mar. 18, 2019, abandoned.
Application 14/604,366 is a continuation of application No. 13/298,407, filed on Nov. 17, 2011, abandoned.
Application 12/366,567 is a continuation in part of application No. 12/323,066, filed on Nov. 25, 2008, granted, now 8,404,235, issued on Mar. 26, 2013.
Application 12/323,066 is a continuation in part of application No. 12/153,612, filed on May 21, 2008, granted, now 7,935,340, issued on May 3, 2011.
Application 12/323,066 is a continuation in part of application No. 12/153,611, filed on May 21, 2008, granted, now 9,056,905, issued on Jun. 16, 2015.
Application 12/323,066 is a continuation in part of application No. 12/124,723, filed on May 21, 2008, abandoned.
Application 12/366,567 is a continuation in part of application No. 12/323,147, filed on Nov. 25, 2008, granted, now 7,906,117, issued on Mar. 15, 2011.
Application 12/323,147 is a continuation in part of application No. 12/153,612, filed on May 21, 2008, granted, now 7,935,340, issued on May 3, 2011.
Application 12/153,612 is a continuation in part of application No. 12/153,611, filed on May 21, 2008, granted, now 9,056,905, issued on Jun. 16, 2015.
Application 12/153,611 is a continuation in part of application No. 12/124,723, filed on May 21, 2008, abandoned.
Application 12/366,567 is a continuation in part of application No. 12/323,194, filed on Nov. 25, 2008, granted, now 8,252,286, issued on Aug. 28, 2012.
Application 12/323,194 is a continuation in part of application No. 12/153,612, filed on May 21, 2008, granted, now 7,935,340, issued on May 3, 2011.
Application 12/153,612 is a continuation in part of application No. 12/153,611, filed on May 21, 2008, granted, now 9,056,905, issued on Jun. 16, 2015.
Application 12/153,611 is a continuation in part of application No. 12/124,723, filed on May 21, 2008, abandoned.
Claims priority of provisional application 60/924,550, filed on May 21, 2007.
Claims priority of provisional application 60/924,551, filed on May 21, 2007.
Prior Publication US 2021/0246201 A1, Aug. 12, 2021
1. A method of treatment of adult respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), sepsis, or systemic inflammatory response syndrome (SIRS) in a subject in need thereof comprising administering to said subject a therapeutically effective amount of an anti-human interleukin-6 (IL-6) antibody or anti-human IL-6 antibody fragment, wherein the antibody or antibody fragment comprises: a variable light chain (VL) polypeptide comprising the complementarity determining regions (CDRs) of SEQ ID Nos: 4, 5, and 6, and a variable heavy chain (VH) polypeptide comprising the CDRs of SEQ ID Nos: 7, 8 or 120, and 9.